Plasma Pen & Fibroblast: FDA Status, Scarring Risk, and Tightening Limits

The search for non-surgical alternatives to surgical blepharoplasty (eyelid lift) and facial skin tightening has led to the popularity of "plasma pen" or "fibroblast" treatments. Marketed as a revolutionary "soft surgery" technique, the procedure promises to contract skin, smooth wrinkles, and lift sagging eyelids without incisions, general anesthesia, or significant downtime.

However, behind the promotional videos of grid-like carbon dots on patients' faces lies a highly volatile clinical landscape. Despite widespread marketing claims, the FDA has not cleared or approved any handheld plasma pen device specifically for cosmetic skin tightening, wrinkle reduction, or non-surgical eyelid lifts.

This article provides an in-depth, evidence-first review of plasma pen safety and regulatory status in 2026. We explain the biophysical mechanism of tissue sublimation, analyze how manufacturers bypass FDA medical device regulation, detail the specific product codes used to register these devices, conduct a raw-data audit of clinical injuries in the FDA MAUDE database, examine state-level scope-of-practice restrictions, and contrast plasma pens with FDA-cleared alternatives for skin tightening.

---

What Is a Plasma Pen? The Biophysical Mechanism

A plasma pen is a handheld device that uses electrical energy to create a high-frequency voltage difference between the device tip and the patient's skin.

The Physics of Plasma

When the tip of the device is held a fraction of a millimeter away from the skin surface, it ionizes the nitrogen and oxygen gas in the surrounding air. This ionization process creates a tiny electrical arc of plasma (often described as the fourth state of matter, consisting of ionized gas molecules).

• Sublimation: The plasma arc discharges thermal energy onto the skin, heating the tissue to extremely high temperatures in a microscopic, localized area. This heat instantly vaporizes or "sublimates" the moisture out of the epidermis (the outer layer of skin), converting solid tissue directly into gas.
• The Carbon Crust: This sublimation process leaves behind a tiny, dark brown or black spot on the skin, commonly referred to as a "carbon crust," "micro-burn," or "dot."
• Wound Healing Cascades: The surrounding and underlying dermis (the deeper layer of skin) experiences controlled thermal damage. This damage triggers an inflammatory cascade, stimulating fibroblasts (the cells responsible for producing structural proteins) to synthesize new collagen and elastin fibers over the following 3 to 6 months.

The Spark-Gap Danger

There is a critical distinction between medical-grade plasma skin regeneration (PSR) systems (such as the Portrait PSR, which uses nitrogen gas canisters to create controlled plasma energy across a broad area) and the handheld "plasma pens" sold in med spas and online:

Most consumer and aesthetic plasma pens are simple spark-gap devices. They do not use a regulated gas source. Instead, they rely on raw electrical discharge. Because there is no gas envelope to stabilize the arc, the energy delivery is highly inconsistent and depends entirely on the manual stability of the operator's hand. If the tip is held slightly too close, it behaves as a direct electrocautery needle, causing deep, uncontrolled third-degree thermal burns in the dermis.

---

The Regulatory Illusion: Cosmetic vs. Regulated Medical Devices

One of the most persistent myths surrounding fibroblast treatment is that the devices are "FDA-approved" for cosmetic skin tightening. This misconception is the result of a deliberate regulatory bypass strategy employed by manufacturers.

The General vs. Medical Classification

The Food, Drug, and Cosmetic Act separates products into "cosmetic devices" and "medical devices" based on their intended use:

• Cosmetic Use: If a device is marketed solely to cleanse, beautify, promote attractiveness, or alter the appearance of the skin without affecting the structure or function of the body, manufacturers often argue it is a cosmetic tool that does not require premarket medical clearance.
• Medical Use: If a device is designed to diagnose, cure, mitigate, treat, or prevent disease, or is intended to affect the structure or function of the body (such as contracting tissue or destroying skin lesions), it is legally classified as a medical device. It must undergo rigorous FDA review via the 510(k) premarket notification or Premarket Approval (PMA) pathways before it can be legally sold.

Warning Letter 632974: Med Pen Concepts, LLC

To bypass the expensive clinical trials required for medical device clearance, many plasma pen manufacturers import their devices under the guise of cosmetic tools or simple "skin tag removers," and then instruct med spa technicians to use them for wrinkle reduction and non-surgical face-lifts.

The FDA has actively cracked down on this practice. On September 15, 2022, the FDA issued a formal Warning Letter (632974) to Med Pen Concepts, LLC regarding their "Plasma MD" and "Plasma +" devices. The agency's investigation revealed that:

• The devices were being promoted on social media and training manuals for unapproved aesthetic indications, including "wrinkle reduction," "skin tightening," and "non-surgical blepharoplasty."
• Because these promotional claims represent an intent to affect the structure of the body (tissue contraction), the products are legally classified as medical devices.
• Because the manufacturer had not obtained the necessary 510(k) clearances or PMA approvals for these cosmetic indications, the devices were declared adulterated and misbranded under federal law.

Health Canada's Ban: Unauthorized for Sale or Use

The regulatory pushback is not limited to the United States. Health Canada has issued clear safety communications stating that plasma pens are not authorized for sale or use in Canada. Under Canadian regulations, these are considered medical devices, and Health Canada has not approved any device model, declaring the importation, advertising, or sale of plasma pens to spas, clinics, or beauty academies illegal. The agency has warned consumers that even when used correctly, these unauthorized devices carry significant risks of permanent scarring, hypopigmentation, skin punctures, and corneal burns. Plasma pens are part of a broader pattern of FDA enforcement on aesthetic energy devices — our coverage of RF microneedling FDA warnings traces a parallel track of safety alerts on a different, but related, device class.

---

FDA Product Codes and Premarket Realities

When a plasma pen manufacturer does register their device with the FDA, they typically register it under product codes that have nothing to do with skin tightening or cosmetic wrinkle reduction.

An audit of the FDA's medical device databases reveals that plasma pens are registered under two primary product codes:

1. Product Code: QAI (Powered Microneedle Device)

• Regulation Number: 21 CFR 878.4430
• Device Class: Class II (Special Controls)
• Intended Use: This code is cleared for powered microneedling platforms designed to treat scars or improve overall skin texture by creating mechanical micro-punctures.
• The Compliance Gap: Several plasma pen manufacturers (such as Louise Walsh International) registered their devices under this code. However, a plasma pen does not use mechanical microneedles. It uses electrical arcs to burn tissue. Registering an electrical arc device under a mechanical microneedling code is a regulatory misalignment that misleads providers into believing the device has been vetted for its actual physical mechanism.

2. Product Code: OHS (Light Based Over The Counter Wrinkle Reduction)

• Regulation Number: 21 CFR 878.4810
• Device Class: Class II
• Intended Use: This code is cleared for low-energy, light-based or LED devices intended for over-the-counter reduction of wrinkles.
• The Compliance Gap: Branded pens like the Plamere Plasma Pen have used this classification. Yet, a plasma pen is not an LED or light-based device; it is a high-voltage electrical discharge tool. The physical mechanism of sublimating tissue and leaving carbon crusts is entirely outside the safety and efficacy parameters evaluated under the OHS light-based code.

[!WARNING] If a provider tells you that their plasma pen is "FDA-approved for skin tightening," ask for the device's 510(k) clearance number. You will find that the device is either unregistered or cleared only as an electrosurgical tool to burn off skin tags, or misclassified under microneedling or light therapy.

---

Under the Hood of FDA MAUDE Reports: Raw Injury Analysis

To understand the real-world clinical risks associated with these devices, we conducted an audit of the FDA’s Manufacturer and User Facility Device Experience (MAUDE) database. MAUDE monitors passive surveillance safety reports submitted by patients, providers, and manufacturers.

A search of MAUDE records reveals severe, permanent patient injuries resulting from fibroblast treatments, specifically highlighting devices registered under the QAI and OHS product codes:

Case Study 1: Plamere Plasma Pen (Report MW5109378)

• Device Classification: OHS (Light-Based Wrinkle Reduction)
• Event Type: Injury
• Patient Profile: 42-year-old Female
• Clinical Outcome: Severe facial scarring and permanent atrophic indentations.
• The Narrative:

  "Severe facial scarring; I had a full face plasma pen treatment with Plamere Plasma Pen that left me with hundreds of small atrophic scars on several areas of my face. The procedure is being done by non-medical technicians who have no skin care training."

• Clinical Analysis: Atrophic scars are depressed, pitted scars that develop when the dermal support structure (collagen and elastin) is destroyed during the healing process. In this case, the electrical arcs delivered by the Plamere pen burned too deeply into the reticular dermis, causing permanent tissue loss. This report also highlights a major systemic risk: the distribution of these high-voltage devices to non-medical technicians who lack basic anatomical training.

Case Study 2: Louise Walsh Plasma Pen (Report MW5095108)

• Device Classification: QAI (Powered Microneedle Device)
• Event Type: Injury
• Patient Profile: 33-year-old (Sex unspecified)
• Clinical Outcome: Pock marks, persistent erythema, cysts, and capillary damage requiring extensive corrective laser treatments.
• The Narrative:

  "I went to an esthetician to have a plasma pen (also known as fibroblast) treatment done on my periorbital wrinkles. The procedure was done on March 7th, and the esthetician used a Louise Walsh Plasma Pen. The treatment left pock marks where each 'carbon crust' was as well as a red mark at the site of each one. The healing process was supposed to only take a week, but mine took 3. As the weeks went on, some of the indentations popped out and became bumps, 3 small cysts arose in the area, and the condition didn't improve... I had a Fraxel Dual laser treatment on May 29th and another on the 15th of this month (June) to correct the marks, discoloration, and small cysts. According to the RN, the redness is from broken capillaries caused by the pen and it requires a different type of laser called the Vbeam." (The reporter's specific dollar costs were redacted from the public MAUDE record.)

• Clinical Analysis: This case illustrates a multi-layered failure cascade. First, the recovery period was three times longer than promised, indicating significant, deep thermal tissue damage. Second, the formation of permanent "pock marks" (atrophic scars) and small cysts (likely epidermal inclusion cysts caused by trapping cellular debris under damaged skin) represents severe structural trauma. Third, the patient suffered from broken capillaries (telangiectasia) due to high-voltage heat damaging delicate blood vessels in the thin skin of the eye area. Correcting the injury required a multi-session laser plan — two Fraxel Dual treatments plus a Vbeam session — which the reporter described as far costlier than the original procedure (the exact dollar figures were redacted in the public record).

Case Study 3: Louise Walsh Plasma Pen (Report MW5108944)

• Device Classification: QAI (Powered Microneedle Device)
• Event Type: Injury
• Patient Profile: 52-year-old Female
• Clinical Outcome: Permanent hypopigmentation (white scars) on the neck.
• The Narrative:

  "I had the Louise Walsh International Plasma Pen procedure done in 2020. This left white scars all over the front of my neck where the procedure was performed."

• Clinical Analysis: Hypopigmentation occurs when the heat from the device destroys the melanocytes (melanin-producing cells in the basal layer of the epidermis). Once melanocytes are destroyed, the skin loses its ability to produce pigment, resulting in permanent, un-pigmentable white spots. The skin of the neck is particularly vulnerable to this type of scarring because it is thin, has fewer sebaceous glands, and has a lower concentration of stem cells required for rapid, scar-free healing compared to the face.

---

Patient Risks and Serious Complications

The raw data from the FDA MAUDE database correlates with the clinical concerns raised by board-certified dermatologists and plastic surgeons. The thermal mechanism of plasma pens carries several high-risk complications.

1. Hypertrophic and Atrophic Scarring

If the electrical arc penetrates beyond the superficial papillary dermis into the deep reticular dermis, the skin cannot regenerate properly. Instead, it replaces normal tissue with disorganized scar tissue:

• Atrophic Scars: Depressed pits that occur when collagen production is insufficient to fill the void left by vaporized tissue.
• Hypertrophic Scars: Raised, firm, red scars that occur when the body produces excessive, abnormal collagen in response to deep thermal burns.

2. Post-Inflammatory Hyperpigmentation (PIH) and Hypopigmentation

Pigmentary changes are the most common complication of plasma pen treatments, particularly in patients with darker skin tones (Fitzpatrick skin types IV–VI):

• PIH: The heat triggers a massive inflammatory response, causing melanocytes to overproduce melanin. This results in dark brown or grey marks at the site of every single carbon dot. These marks can last for 6 to 12 months and often require medical-grade topical hydroquinone or chemical peels to resolve.
• Hypopigmentation: Conversely, if the heat is too intense, it kills the melanocytes entirely. This leaves permanent, chalky white spots that cannot be camouflaged by tanning.

3. Ocular Risks and Eyelid Dangers

Many plasma pen treatments are performed directly on the upper and lower eyelids (non-surgical blepharoplasty). The skin of the eyelid is the thinnest on the human body, measuring less than 0.5 mm in thickness.

• Depth of Penetration: Because the skin is so thin, the risk of burning completely through the eyelid tissue is exceptionally high.
• Corneal Burns and Vision Loss: If the electrical arc slips or if the technician does not use corneal shields (protective metal contact lenses placed over the patient's eyes during laser procedures), the electrical energy can cause direct corneal burns, scarring, and permanent vision impairment.

4. Infections and Delayed Healing

Each carbon crust represents a micro-wound that exposes the underlying dermis to pathogens.

• Bacterial Infection: Inadequate post-care or non-sterile environments can introduce Staphylococcus aureus or Pseudomonas aeruginosa, leading to oozing, honey-colored crusts, and increased scarring risk.
• Viral Reactivation: The heat from the device can trigger a severe outbreak of the herpes simplex virus (cold sores) in patients who carry the virus, which can spread rapidly across the raw, burned skin of the face.

---

Legality and Scope of Practice: Can Estheticians Perform This?

The legal authority to perform plasma pen treatments is highly fragmented and varies by state. In the United States, professional licensing boards (such as the Board of Cosmetology and the Board of Medicine) determine who can operate specific devices.

The Medical Device Standard

In almost all jurisdictions, if a device is classified as a regulated medical device (Class II or Class III) or acts by destroying skin tissue (ablation/sublimation), its use constitutes the practice of medicine.

• Esthetician Restrictions: In states like California, Florida, and Texas, licensed estheticians are legally restricted to the superficial epidermis. They are strictly prohibited from performing procedures that damage or ablate the skin, meaning estheticians cannot legally operate plasma pens.
• The Telehealth Loophole: To bypass these laws, some med spas employ a medical director (a physician who is paid a monthly fee to sign off on protocols) and argue that the esthetician is operating under delegated medical authority. However, many state medical boards have ruled that medical delegation is only legal for licensed medical professionals (such as RNs, NPs, or PAs) and cannot be extended to unlicensed or cosmetology-licensed estheticians.

Operating a plasma pen outside your state board's scope of practice can result in immediate license revocation, heavy fines, and the complete denial of malpractice insurance coverage in the event of a patient injury.

---

Clinical Alternatives: FDA-Cleared Non-Surgical Tightening Platforms

Patients seeking skin tightening or wrinkle reduction do not need to accept the high scarring risks of unverified plasma pens. Several FDA-cleared medical devices offer proven clinical efficacy and built-in safety mechanisms:

1. Micro-Focused Ultrasound (Ultherapy)

Ultherapy is FDA-cleared for non-invasive lifting of the neck, chin, and brow.

• How it works: It uses micro-focused ultrasound waves to target the deep structural layers of the skin, including the SMAS (Superficial Muscular Aponeurotic System)—the same layer tightened during a surgical facelift.
• Safety Advantage: It bypasses the surface of the skin entirely, delivering heat deep beneath the epidermis. This makes it highly safe for all skin types (Fitzpatrick I-VI) with virtually zero risk of surface scarring or hyperpigmentation.

2. Synchronous Ultrasound Parallel Beam (Sofwave)

Sofwave is FDA-cleared for lifting the brow, submental tissue, and neck, and improving facial lines.

• How it works: It delivers parallel beams of ultrasound energy at a depth of 1.5 mm in the mid-dermis, producing a 3D thermal zone that contracts collagen.
• Safety Advantage: It features integrated cooling (Sofcool) that protects the outer layer of the skin from burning, making it safe for darker skin types.

3. Monopolar Radiofrequency (Thermage FLX)

Thermage is FDA-cleared for non-invasive wrinkle reduction and treatment of the eyelids.

• How it works: It uses radiofrequency energy to heat the collagen-rich layers of the dermis, causing immediate tissue contraction and long-term collagen synthesis.
• Safety Advantage: It uses a bulk heating mechanism with active cooling sprays to ensure the epidermis is protected while the deeper layers are heated.

4. Fractional CO2 Laser Resurfacing

For patients willing to undergo 7 to 10 days of downtime to treat wrinkles and scars, fractional CO2 lasers (such as the Fraxel or Lumenis UltraPulse) provide a much safer, more controlled option than plasma pens (see our guide to CO2 laser resurfacing complications for what to expect and what to avoid).

• How it works: The laser uses computerized scanner patterns to deliver precise, micro-beams of light energy. The depth, density, and thermal overlap are controlled by advanced software, eliminating the operator-error risks associated with manual plasma pen arcs.

---

Summary FAQ

Is fibroblast skin tightening FDA approved?

No. The FDA has not cleared or approved any handheld plasma pen or fibroblast device specifically for cosmetic skin tightening, eyelid lifting, or non-surgical wrinkle reduction. While some devices are cleared under product codes for microneedling, light-based wrinkle therapy, or electrosurgical lesion removal (such as skin tags), marketing them for cosmetic "fibroblasting" or "tissue tightening" represents an unapproved, off-label promotion that has resulted in FDA warning letters to manufacturers.

Can a plasma pen treat sebaceous hyperplasia or spider veins?

No. Using a plasma pen to treat sebaceous hyperplasia (enlarged oil glands) or spider veins is highly dangerous and ineffective. Plasma pens generate uncontrolled superficial heat that can cause severe, permanent atrophic scarring or hyperpigmentation on the face. Spider veins require targeted vascular lasers (like the KTP or PDL/Vbeam) that target hemoglobin without burning the surrounding skin. Sebaceous hyperplasia is best treated by low-temperature electrocautery or specific dermatological lasers under the supervision of a board-certified dermatologist.

---

Sources

• U.S. Food and Drug Administration. Warning Letter: Med Pen Concepts, LLC (September 15, 2022). Letter Ref: 632974. Available at: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/med-pen-concepts-llc-632974-09152022
• U.S. Food and Drug Administration. MAUDE Adverse Event Report: Louise Walsh International Plasma Pen (MDR Report Key: 10179046, Report Number: MW5095108). Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/detail.cfm?mdrfoi__id=10179046&pc=QAI
• U.S. Food and Drug Administration. MAUDE Adverse Event Report: Plamere Plasma Pen (MDR Report Key: 14218771, Report Number: MW5109378). Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/detail.cfm?mdrfoi__id=14218771&pc=OHS
• U.S. Food and Drug Administration. MAUDE Adverse Event Report: Louise Walsh International Plasma Pen (MDR Report Key: 14104768, Report Number: MW5108944). Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/detail.cfm?mdrfoi__id=14104768&pc=QAI
• U.S. Food and Drug Administration. FDA Aesthetic Cosmetic Devices Product Index. Available at: https://www.fda.gov/medical-devices/products-and-medical-procedures/aesthetic-cosmetic-devices
• U.S. Food and Drug Administration. 510(k) Premarket Notification Database. Product Codes: QAI, OHS, GEX. Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm
• American Society for Dermatologic Surgery. Position Statement on Esthetician Scope of Practice and Medical Devices.
• Ganceviciene R, Liakou AI, Theodoridis A, et al. Skin anti-aging strategies. Dermatoendocrinol. 2012;4(3):308-319. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC3583892/
• Health Canada. Plasma pens are not authorized in Canada and may pose health risks. Public advisory (originally issued November 26, 2018; subsequently updated). Available at: https://recalls-rappels.canada.ca/en/alert-recall/plasma-pens-are-not-authorized-canada-and-may-pose-health-risks